What is berberine, and what does the research say?

Last reviewed: 7 May 2026

Berberine has become one of the most-searched supplement ingredients in the UK over the past two years. Most of the attention comes from viral social media framing it as "nature's Ozempic" — a claim that has run well ahead of the evidence, and from a UK regulatory standpoint has nothing to do with what a berberine supplement is allowed to promise.

This article steps past the hype and walks through what berberine is, what research is genuinely looking at, what the regulator says, and what to think about if you are considering it.

What berberine is

Berberine is a plant alkaloid — a bitter, bright-yellow compound found in the root and bark of a handful of plants, most commercially Berberis aristata (Indian barberry), and also in goldenseal (Hydrastis canadensis), Oregon grape (Mahonia aquifolium), and tree turmeric (Berberis vulgaris). In supplement form it is almost always presented as berberine hydrochloride (HCl), a stable salt that dissolves and handles more predictably than the free base. A 98% standardised extract is the common quality benchmark — it tells you that the active alkaloid makes up 98% of the raw extract material.

A few millennia of traditional use

Berberine-containing plants have a long history in traditional medicine systems. In Ayurveda, Berberis aristata (known locally as daruharidra) has been used for centuries. In traditional Chinese medicine, the berberine-rich root of Coptis chinensis is called huanglian — "yellow link" — and appears in classical formulations dating to well before the common era. None of this historical usage constitutes modern clinical evidence of efficacy; it does, however, explain why berberine has been in food-supplement use across Europe long enough to have a reasonable safety profile in normal dietary-supplement doses.

AMPK — the single mechanism everyone cites

If you read any content about berberine, you will run into AMPK. AMP-activated protein kinase is an enzyme inside your cells that acts as an energy-status sensor. When cellular energy drops, AMPK activates and nudges a set of downstream processes that, collectively, shift cells toward energy conservation and efficient use of glucose and fat. It is sometimes called the cellular "master switch" for energy balance.

Berberine is one of several natural compounds that can activate AMPK. That activation has been characterised in cell and animal studies, and increasingly in human studies measuring downstream biochemistry. This is why virtually every berberine article goes straight to AMPK — it is a legitimately interesting mechanism, and it is where the research starts.

Two caveats worth keeping in mind:

AMPK activation happens in many tissues and does many things. A compound that activates AMPK does not produce a single, neat outcome in the body; it produces a cluster of biochemical effects that interact with your diet, exercise, other medications and individual physiology.
Mechanism is not outcome. AMPK activation in a petri dish or in a mouse does not automatically translate into a measurable change in a person's health markers, let alone a product benefit. Responsible content keeps those levels separate.

Where research is genuinely active

Berberine is an active research area in several directions — all best framed as "studies have examined" rather than as product claims:

Glucose and insulin biochemistry. Trials have measured changes in fasting glucose, postprandial glucose, HbA1c and insulin sensitivity indices in populations with metabolic dysfunction. A small head-to-head trial in adults with type 2 diabetes reported that 0.5 g of berberine three times daily produced reductions in HbA1c and fasting/postprandial glucose comparable to metformin over three months ^[1]. A subsequent meta-analysis of 27 randomised trials (n=2569) concluded that berberine combined with lifestyle intervention performed similarly to oral hypoglycaemic, lipid-lowering and antihypertensive drugs across the pooled trials ^[2].
Lipid and triglyceride markers. Studies have tracked changes in total cholesterol, LDL and triglycerides in overlapping populations, with similarly heterogeneous effect sizes ^[2].
Gut microbiota. Newer research has examined how berberine — which is very poorly absorbed systemically — interacts with the gut microbiome before much of it ever reaches the bloodstream. This is a genuinely interesting emerging area.
Cellular stress and inflammatory markers. Pathway-level work continues; clinical translation is earlier-stage.

What none of this research does is license a product claim. The findings sit in the research literature. A food supplement sold in the UK or EU cannot, legally, tell you that berberine manages blood sugar, lowers cholesterol, causes weight loss, or treats any specific condition. That framing is reserved for authorised medicines ^[3].

The "nature's Ozempic" narrative

A TikTok-era framing of berberine as a natural substitute for GLP-1 medications like semaglutide (Ozempic) has been responsible for most of the recent UK search volume. The framing is catchy and it is also regulatory and clinical overreach.

The two agents work through completely different biology. GLP-1 receptor agonists are engineered peptides that activate a specific receptor pathway in the gut and brain. Berberine is a plant alkaloid that, among other things, activates AMPK. They are not pharmacological analogues.
The effect sizes reported for berberine in the published literature — where they reach significance at all — are orders of magnitude smaller than the clinical effects documented for GLP-1 medications in weight-management trials.
"Weight loss" is a tightly regulated claim category in the UK and EU. Very few ingredients hold authorised weight-management claims; berberine is not one of them ^[4].

If you arrived at berberine through that narrative, the honest read is: there is real research, it is interesting, and it does not yet justify the comparison.

What the regulators say

The UK GB Nutrition and Health Claims register and the EU equivalent list every health claim a food supplement is legally permitted to make ^[4]. Authorised claims exist for vitamins and minerals where the science has been formally reviewed and accepted (vitamin D for bones, vitamin C for the immune system, and so on). For berberine, the register currently contains no authorised claims at all.

That fact does not mean berberine "doesn't work" — it means the authorised-claims process and the research literature are currently not aligned. Responsible supplement content sits inside what is allowed: information on what berberine is, how it is traditionally used, what researchers are investigating, and practical considerations for anyone taking it. Claims beyond that, on any UK-facing supplement page, are outside the rules ^[3].

How to read a berberine label

Once you know what to look for, comparing two bottles is straightforward.

Standardisation. Look for "berberine HCl, standardised to 98%" or an equivalent specification. Less-specific labels ("berberine extract") tell you less about what is in the capsule.
Dose per capsule. The range on the UK market is typically 250 mg to 500 mg of standardised berberine HCl per capsule.
Source plant named. Berberis aristata, Berberis vulgaris, and Coptis chinensis are all legitimate raw materials; the plant should be on the label.
Third-party testing. A certificate of analysis covering heavy metals, microbial purity, and alkaloid content is standard at the quality end of the market.
No medicinal claims on the pack. A brand that makes health claims berberine is not allowed to make is either ignorant of the rules or indifferent to them. Neither is a good sign.

Where our berberine fits

Our Berberine HCl 98% capsules use Berberis aristata (Indian barberry) root extract standardised to 98% berberine HCl, 500 mg per capsule. Sold as a food supplement without any disease or outcome claims on the label — because, under UK and EU rules, those would not be legal to make.

Safety, interactions, who should be careful

Berberine is generally well tolerated at typical supplement doses. The commonly reported side effects in the research literature are gastrointestinal — cramping, loose stools, nausea — especially when starting at the upper end of the dose range ^[1]. Splitting a daily dose across meals usually reduces those effects.

Several interactions matter:

CYP3A4 and P-glycoprotein. Berberine inhibits both, similarly to piperine. That means it can raise blood levels of drugs processed by those pathways — including some statins, calcium-channel blockers, immunosuppressants (for example cyclosporine), and certain antidepressants. If you are on a regular prescription medication, talk to your prescriber before starting berberine.
Hypoglycaemic medications. Because of berberine's effects on glucose-related biochemistry, people taking insulin or sulfonylureas are advised to involve their doctor — the interaction is dose-sensitive and worth professional oversight.
Pregnancy and breastfeeding. Not recommended — berberine can cross the placenta, and adequate safety data in these populations is lacking.
Bilirubin metabolism in newborns. Berberine can displace bilirubin from albumin binding, which is why it is not used in infants.

In practice

Berberine is an interesting plant compound with a real research literature and a long traditional-use history. It is also the subject of a social-media hype cycle that has outrun both the evidence and the law on what a food supplement is allowed to say.

The practical position: treat berberine as what it is — a food supplement with an active mechanism (AMPK), a genuinely active research field, and zero authorised product claims under UK/EU law. Read labels carefully, talk to your doctor if you are on other medication, and ignore the Ozempic comparisons.

If that is the brief you were looking for, our Berberine HCl 98% is a 500 mg standardised capsule from Berberis aristata root — sold for what it is, not for what the internet says it is.

References

Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717. PubMed: 18442638
Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81. PubMed: 25498346
UK Nutrition and Health Claims Regulations 2007. legislation.gov.uk
European Commission. EU Register of Nutrition and Health Claims Made on Foods. ec.europa.eu